{"id":480865,"date":"2020-04-22T22:56:01","date_gmt":"2020-04-22T22:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=480865"},"modified":"2020-04-22T22:56:01","modified_gmt":"2020-04-22T22:56:01","slug":"glioblastoma-multiforme-market-size-share-trend-epidemiology-market-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/glioblastoma-multiforme-market-size-share-trend-epidemiology-market-forecast-to-2030_480865.html","title":{"rendered":"Glioblastoma Multiforme Market Size, Share, Trend, Epidemiology & Market Forecast to 2030"},"content":{"rendered":"
\"Glioblastoma<\/a><\/p>\n
\n
Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Glioblastoma multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

According to the American Brain Tumor Association, Glioblastomas (also called GBM) are malignant Grade IV tumors, where a large portion of tumor cells reproduce and divide at any given time. The tumor is predominantly made up of abnormal astrocytic cells, which also contain a mixture of different cell types (including blood vessels) and areas of dead cells (necrosis). Glioblastomas are infiltrative and invade into nearby regions of the brain. They can also sometimes spread to the opposite side of the brain through connection fibers (corpus callosum). <\/p>\n

The symptoms of GBM vary depending on the location of the brain tumor such as persistent headaches, double or blurred vision, vomiting, loss of appetite, changes in mood and personality, changes in ability to think and learn, new onset of seizures, speech difficulty of gradual onset, etc.The diagnosis of GBM mainly includes use of neurological examinations, imaging tests and excising a sample of tissue for testing, i.e, biopsy.<\/p>\n

The mainstay of treatment for GBM is surgery, followed by radiation and chemotherapy. The primary objective of surgery is to remove as much of the tumor as possible without injuring the surrounding normal brain tissue needed for normal neurological function (such as motor skills, the ability to speak and walk, etc.).<\/p>\n

The Glioblastoma multiforme market report covers emerging drugs, current treatment practices, Glioblastoma multiforme market share of the individual therapies, current and forecasted Glioblastoma multiforme Market Size from 2017 to 2030 segmented by seven major markets. <\/p>\n

The report also provides detailed current Glioblastoma multiforme treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/p>\n

 <\/span><\/span><\/p>\n

Glioblastoma Multiforme Market Key Facts<\/span><\/strong><\/p>\n

Glioblastoma (GBM) is the most aggressive malignant primary brain tumor. With an incidence rate of 3.19 per 100,000 persons in the United States and a median age of 64 years, it is uncommon in children. <\/span><\/p>\n

GBM has a high rate of recurrence, occurring in about 90% of patients. In addition, GBM increases with age and affects more men than women.<\/span><\/p>\n

The total incident population of Glioblastoma Multiforme in the seven major markets was found to be 28,886 in 2017, which is expected to increase by 2030. While the total diagnosed incident population of Glioblastoma Multiforme in the 7MM was 25,998 in 2017.<\/span><\/p>\n

Glioblastoma (GBM) is the most aggressive malignant primary brain tumor. With an incidence rate of 3.19 per 100,000 persons in the United States and a median age of 64 years, it is uncommon in children. <\/span><\/p>\n

 \"Glioblastoma<\/span><\/span><\/p>\n

Visit For Sample Pages: <\/span><\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market<\/a><\/p>\n


Key Benefits of Glioblastoma Multiforme Market Report<\/strong><\/span><\/span><\/p>\n

Glioblastoma multiforme market report provides an in-depth analysis of Glioblastoma multiforme Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.<\/span><\/p>\n

The Glioblastoma multiforme market report will help in developing business strategies by understanding the Glioblastoma multiforme Market trends & developments, key players and future market competition that will shape and drive the Glioblastoma multiforme market in the upcoming years.<\/span><\/p>\n

The Glioblastoma multiforme market report covers Glioblastoma multiforme current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.<\/span><\/p>\n

The report provides a detailed assessment of the Glioblastoma multiforme market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. <\/span><\/p>\n

 <\/span><\/span><\/p>\n

Glioblastoma Multiforme Market<\/a><\/p>\n

The Glioblastoma multiforme market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Glioblastoma multiforme market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. <\/span><\/p>\n

 The report gives a thorough detail of Glioblastoma multiforme market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. <\/span><\/p>\n

 <\/span><\/span><\/p>\n

Glioblastoma Multiforme Epidemiology<\/a><\/p>\n

The Glioblastoma multiforme epidemiology section covers insights about historical and current Glioblastoma multiforme patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.<\/span><\/p>\n

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  <\/span><\/p>\n

 <\/span><\/p>\n

Glioblastoma Multiforme Drugs Uptake and Key Market Players<\/a><\/p>\n

The Glioblastoma multiforme Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioblastoma multiforme market or expected to get launched in the market during the study period. The analysis covers Glioblastoma multiforme market uptake by drugs; patient uptake by therapies; and sales of each drug.    <\/span><\/p>\n

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. <\/span><\/p>\n

 <\/p>\n

The dynamics of GBM market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected during the forecast period of 2020-2030<\/p>\n

 <\/p>\n

Companies like Bristol Myers Squibb, DelMar Pharmaceuticals, AbbVie, Diffusion Pharmaceuticals, Apogenix, DNAtrix, Kazia Therapeutics, Medicenna Therapeutics and others are coming up with novel therapeutic approaches that can entirely change the treatment landscape of GBM.<\/span><\/p>\n

 <\/p>\n

Table of Contents<\/span><\/strong><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary <\/span><\/p>\n

3. Glioblastoma Multiforme Competitive Intelligence Analysis<\/span><\/p>\n

4. Glioblastoma Multiforme Market Overview at a Glance<\/span><\/p>\n

5. Glioblastoma Multiforme Disease Background and Overview<\/span><\/p>\n

6. Glioblastoma Multiforme Patient Journey<\/span><\/p>\n

7. Glioblastoma Multiforme Epidemiology and Patient Population<\/span><\/p>\n

8. Glioblastoma Multiforme Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

9. Glioblastoma Multiforme Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Glioblastoma Multiforme Treatment<\/span><\/p>\n

11. Glioblastoma Multiforme Marketed Products<\/span><\/p>\n

12. Glioblastoma Multiforme Emerging Therapies<\/span><\/p>\n

13. Glioblastoma Multiforme Seven Major Market Analysis<\/span><\/p>\n

14. Attribute Analysis<\/span><\/p>\n

15. Glioblastoma Multiforme Market Outlook (7 major markets)<\/span><\/p>\n

16. Glioblastoma Multiforme Access and Reimbursement Overview<\/span><\/p>\n

17. KOL Views on the Glioblastoma Multiforme Market.<\/span><\/p>\n

18. Glioblastoma Multiforme Market Drivers<\/span><\/p>\n

19. Glioblastoma Multiforme Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

 <\/span><\/span><\/p>\n

About <\/strong>DelveInsight<\/a><\/p>\n

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

 <\/span><\/span><\/p>\n

Related Reports-<\/strong><\/p>\n

Glioblastoma multiforme (GBM) Epidemiology Forecast to 2030<\/strong><\/p>\n

DelveInsight’s Glioblastoma multiforme (GBM) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Glioblastoma multiforme (GBM) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/span><\/p>\n

 <\/p>\n

Glioblastoma multiforme (GBM) Pipeline Insights, 2020<\/strong><\/p>\n

Glioblastoma multiforme (GBM) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Glioblastoma multiforme (GBM) market.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Anuj Rawat
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Delveinsight Business Research DelveInsight’s “Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Glioblastoma multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU5 (Germany, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,404],"tags":[],"class_list":["post-480865","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/480865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=480865"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/480865\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=480865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=480865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=480865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}